
|Videos|September 10, 2019
Optimal Management of Early-Stage HCC
Advertisement
Episodes in this series
Key Takeaways:
The importance of multidisciplinary management of the underlying liver disease and function as well as the tumor burden in patients with hepatocellular carcinoma (HCC).
Solidifying interactions among locoregional practitioners, interventional radiologists, medical oncologists, and hepatologists to help define when to cease TACE (transarterial chemoembolization) and start a patient on systemic therapy.
Triggers to discontinue locoregional therapy and move to systemic therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
3
OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
4
Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer
5





















































